Blood pressure (BP) control remains unsatisfactory worldwide. Better knowledge of BP management in clinical practice is needed to develop more effective improving strategies. Using a large Italian primary care database, we selected the subjects diagnosed with hypertension, and extracted the diagnosis of myocardial infarction, angina pectoris/coronary disease, stroke/transitory ischemic attack (TIA), heart failure, atrial fibrillation, peripheral arterial disease, diabetes mellitus, the serum total cholesterol, HDL cholesterol, triglycerides, creatinine, BP, electrocardiogram, weight, height and the prescription of cardiovascular (CV) 
Introduction
It is well known that hypertension is one of the most important modifiable risk factor for atherothrombotic cardiovascular (CV) disease; 1 unfortunately blood pressure (BP) control is unsatisfactory worldwide and particularly in Europe. 2 The barriers for controlling hypertension are well known and include patient factors, such as non-adherence to lifestyle advice or drug treatment, and healthcare provider factors, including the organisation or environment where care is delivered. As far as the factors pertaining to physicians are concerned, suboptimal drug prescription, and particularly therapeutic inertia, is of paramount importance. According to the guidelines, 3 decisions about the treatment intensity should consider the patient's risk level and the corresponding health benefit expected from the therapy. Surprisingly, the relationship between risk level/expected benefit and prescribing attitude is not considered in recent reviews on improvement of BP control. [4] [5] For these reasons, the usual evaluation of clinical practice based on the percentage of 'controlled' or 'non-controlled' patients, (defined as such according to a BP threshold) appear to be of limited help. Furthermore, because of the continuous relationship between BP levels and CV risk, the absolute BP level is more relevant than simply being above or below the recommended BP target. On the patient's side, non-attendance obviously impairs all the physician's efforts to reach the optimal treatment levels for hypertension. This problem is hardly considered when the level of hypertension control is evaluated. 2 Information about real practice problems in hypertension management are crucial to develop new and more effective improvement strategies. The vast majority of hypertensive patients are managed in primary care, and almost all the drug prescriptions are filled by General Practitioners (GPs) in Italy. We examined a large primary care database to analyse the BP management in Italy.
Methods
We conducted a retrospective study using information obtained from the Health Search Database, set up by the Italian College of GPs in 1998. The quality of the information gathered has been assessed in earlier studies. 6, 7 In Italy, all the citizens are registered with a GP or with a Paediatrician, depending on their age. All the 'life saving' drugs are reimbursed by the National Health Service and, as far as hypertension is concerned, almost all the prescription are filled by GPs. The Health Search Database currently contains data from over 550 GPs, representing more than 40 000 Italian GPs, with a patient population of more than 800 000 individuals. Following the training in the optimal use of the clinical software, all participating GPs have been recording all patients' data during their normal daily clinical practice, that is, the complete recording of all patients' data, according to the guidelines, is not a requirement, and therefore, only the spontaneous clinical activity is recorded. For this reason, the reported prevalence is not the true prevalence of the diseases, but the prevalence of detected and recorded diagnoses. This may be an important limitation for pure epidemiological studies, but a strength when an accurate and generalizable picture of the real practice is needed. All the complete, original and anonymous clinical records are periodically sent to the database. All the diagnoses are coded using the ninth revision of the International Classification of Diseases (ICD-9). 8 Prescription records are coded according to the Anatomical Therapeutic Chemical classification system. 9 A unique patient code links demographic, prescription information, clinical events and diagnoses, hospital admissions and cause of death. Data are periodically subjected to quality control, exploring four realms: (a) recorded basic data (smoking habits, weight and height), (b) prescriptions associated with a clinical problem, (c) codified diagnoses and (d) prescribed test with associated recorded results. 10 Any variations within the agreed ranges are investigated and submitted to each participating GP. Physicians who fail to meet the quality standard criteria required are not considered for epidemiological studies. 11 At the time of the initiation of this study, 400 GPs were considered up to standard and only their patients were the subjects of this study. We selected all the living subjects on 31 12 Prescriptions (at least one in the last 4 months) of the CV drugs were also examined.
Statistical analysis
We used a standard descriptive analysis (means and confidence intervals), the w 2 -test (to examine differences in the drug pattern prescription between controlled and non-controlled patients) and the correlation coefficient (to examine the correlation between the number of prescribed drugs and the level of CV risk).
Results
In this study, we have only reported the results concerning BP control and drug prescription. First, we identified the patients with evaluable BP level (that is, subjects with recorded BP values in 2005) and those with controlled (o140/90 mm Hg) or noncontrolled (X140/90 mm Hg) BP; then, we examined the prescription pattern and the mean BP values according to the risk level (High risk vs non-high risk) and the hypertension classification (grades according to the guidelines), 7 both in controlled and non-controlled patients.
The 400 GPs cared for 615 373 subjects. The different classes of antihypertensive drugs prescribed in controlled and non-controlled patients are reported in Table 1 .
The number of prescribed drug is significantly higher in high-vs low-risk risk patients for each hypertension grade (Table 2 ).
More interestingly, there is a highly significant (R 2 ¼ 0.9426) linear relationship between the level of CV risk and the mean number of prescribed antihypertensive drugs (Figure 1 
Discussion
International guidelines on hypertension treatment are regularly issued every few years, not to mention thousands of congresses and educational meetings. Despite this huge effort, millions of patients do not reach the recommended BP targets, especially in Europe, 2 and BP suboptimal control is still causing thousands of potentially avoidable CV events every year. The hypertensive subjects are usually classified as 'controlled' or 'not controlled'. In our opinion, this is not an adequate method to describe the problem, thus impairing the development of effective improvement strategies. Knowledge of the relevant variables, such as coexisting diseases, the level of CV risk, the degree of BP control and the drugs prescribed, are important to better understand the reasons of suboptimal treatment. This information should be obtained in the setting where hypertensive patients are usually cared for, that is, in general practice. We, therefore, used a large primary care database to investigate how Italian GPs treat their hypertensive patients. Surprisingly, the most important problems in hypertension management seem to be the low attendance rate of hypertensive patients and BP under-recording by GPs. Even if many of the subjects without BP, a recorded BP had this taken at some point during their treatment, the lack of an up to date record greatly impairs the effective management of hypertension. The magnitude of these problems does not change even when some of the non-attending subjects were hause-bound and possibly well controlled at home. It is clear that any strategy aimed at improving BP control cannot work if 44% of the hypertensive patients have unknown BP values. We think that the approach to this huge shortcoming should involve both the GPs and the Health Authorities. A pay-for-performance contract for GPs 13 can significantly increase the BP recording rate, 14 and, on the other hand, solo or group practices can improve their performances adopting simple an unexpensive self auditing procedures. 15 Both approaches could increase the number of patients with recorded BP values and possibly reduce the number of non-attainders, focusing GPs on the need to better motivate and involve their hypertensive patients.
Among the subjects whose BP was recorded, 43% had uncontrolled BP. The prescription of antihypertensive drugs in non-controlled patients is suboptimal. Even if the number of drugs raises significantly with the increases in BP levels and in CV risk, the magnitude of under-prescription is enormous. This is a well-known problem. A recent survey in the United States 16 showed that although the treatment rate of patients with diabetes mellitus, coronary artery disease, stroke and chronic kidney disease is higher than that of non-high-risk subjects, lack of therapy remains unacceptable-from 10.6 to 34.1% depending on the associated disease, a percentage very close to ours.
Our data clearly showed that the problem of the inadequate control of hypertension should be viewed under two different perspectives: that of the single doctor/patient and that of the public health management.
Considering the clinical practice of the GPs, therapeutic inertia-the failure to start new drugs or increasing the dose in patients with an abnormal clinical measurement- 17 seems to be playing a pivotal role; this is a well-known phenomenon.
Observational studies in the United States have found that therapeutic inertia is common in hypertension, diabetes and hypercholesterolaemia. Therapeutic inertia can even persist when BP is quite high; in a recent large US study, one-third of patients with persistent BP X160/100 mm Hg had no changes in their treatment or had a spontaneous return to lower BP over 6 months (although the study did not examine whether this reflected prescribing decisions or patient adherence). 18 This trend also was confirmed in Europe. In a British study, the treatment was not intensified in nearly half (45%) of consultations in which the patients had a single suboptimal BP reading. Similarly, no intensification occurred in 36% of consultations after two successive suboptimal BP readings, and in 27% of those taking fewer than three drugs. 19 In our study, only 21% of non-controlled patients were prescribed with X3 drugs, showing that therapeutic inertia is a major problem also in Italian primary care. Of most concern also is the under-prescription among grade 3 hypertensive and high-risk patients.
On the other hand, it must be noticed that over three quarter of the non-controlled patients have grade I hypertension, most of them with BP values o150/90 mm Hg; this BP level is considered satisfactory according to the standards of the British GPs. Furthermore, most of our grade 1 hypertensive patients are non-high risk individuals with a mean BP very close to that recommended by the guidelines. For these patients, the individual odds of benefit from small BP decreases are low. Furthermore, to reach the current targets, many patients will require up to four drugs, with many also taking aspirin and a statin (five or six drugs in total), but in terms of lowering CV risk, which is the purpose of treatment, the benefits from adding a fifth, or even a sixth drug, are scant. 20 Additional drugs have diminishing benefit, but an equal or greater chance of side effects and interactions. It is not, therefore, surprising that both doctor and patients are not eager to increase the number of daily tablets. On the other hand, such an effort could be justified for high-CV risk patients, for whom a small BP decrease offers the greater benefit. This study shows that the number of prescribed drugs is, in fact, higher for high-risk and for grade 2-3 hypertensive patients. Despite this, according to our data, X2 additional antihypertensive drugs could be necessary to aim to the target BP recommended for high-CV risk patients; 3 this is a relevant effort for patients, GPs, and National Health Services. Computer-based strategies [21] [22] could be a useful tool both to identify the high-risk patients and to remind the GP to increase the antihypertensive therapy (and to check patient compliance).
According to the Cochrane Collaboration, 23 antihypertensive drug therapy should be vigorously increased when patients do not reach target BP levels. In our opinion, this therapeutic approach would not suit the cases of the great number of low-risk, grade 1 hypertensive patients, for whom the individual benefit of a further BP reduction is small. Should we be happy with a o150/90 mm Hg BP, accepting real practice and British GPs contract standards, or should we struggle to reach guidelines' targets? We think that only the Governments can answer this question, as the advantages of such a strategy are relevant when the whole population is considered. The availability of low-cost, well-tolerated and safe drugs make this option attractive and cost effective. It is clear that such a population strategy should be agreed with doctors and patients, and adequately supported by the National Health Service.
Our study has many limits. We examined the data form GPs who volunteered to participate to a research database; it is, therefore, probable that the recording rate of BP and CV risk factors is higher than that of the other Italian GPs; on the other hand, the prescription pattern of these GPs does not differ from that of the other Italian GPs.
We must also remember that o140/90 mm Hg is not the target for high-risk patients, according to the international guidelines. 3 The rate of BP control in these patients is thus overestimated. On the other hand, in clinical practice, some patients have their BP measured in non-ideal condition; therefore, there is the possibility of overestimating the rate of noncontrol.
We did not examine the therapeutic adherence. Successful BP control is possible with a combination of intensification and adherence, suggesting that the therapy intensification must be coupled with interventions to enhance medication adherence. 24 Unfortunately, both persistence 25 and adherence 26 are low among Italian hypertensive patients; it is, therefore, possible that these problems play a relevant role in BP under-control.
It must be also noticed that even with politherapy and good therapeutic adherence, current targets are low enough to be unachievable for most patients. Even in clinical trials, with protocol driven prescribing and willing participants, most fail to achieve systolic BP below 140 mm Hg. 27 Even if 100% control is not possible, our data about the prevalence of renal failure and diuretic use in noncontrolled patients clearly show that the identification of low GFR and a more rationale use of loop diuretics can be a simple and easy improvement strategy.
Conclusions
Low attendance rate of hypertensive patients, and BP under-recording are major obstacles to hypertension control, and should be immediately addressed both by the Health Authorities and GPs. The use of politherapy increases on accordance with the risk level, but remains largely suboptimal, both among low-and high-CV risk patients, thus representing a valuable target for improvement. Most uncontrolled individuals are non-high-CV risk, grade 1 hypertensive patients, for whom the single personal benefit of adding another drug is modest; however, increasing the therapy in such a great number of people can lead to a relevant nationwide decrease of CV events. Different improving strategies should therefore be developed for low-risk subjects and for grade 2-3 hypertensive/high-CV risk patients.
